Nasal Cannula Market - By Type (Low, High), By Material (Plastic, Silicone), Application (Acute Respiratory Failure, COPD, Bronchiectasis, Sleep Apnea), End use (Hospital, Specialty Clinic, Long Term Care Center, ASC, Homecare) – Global Forecast, 2023-2032

Nasal Cannula Market - By Type (Low, High), By Material (Plastic, Silicone), Application (Acute Respiratory Failure, COPD, Bronchiectasis, Sleep Apnea), End use (Hospital, Specialty Clinic, Long Term Care Center, ASC, Homecare) – Global Forecast, 2023-2032

Nasal Cannula Market Size

Nasal Cannula Market was valued at USD 7.5 billion in 2022 and is poised to grow at a CAGR of over 6.2% from 2023 to 2032. A nasal cannula is a medical device used to deliver supplemental oxygen to individuals that require increased oxygen levels in their bloodstream. It is a lightweight, flexible tube that typically consists of two prongs that are inserted into the nostrils. The other end of the tube is connected to an oxygen source, such as an oxygen cylinders and concentrators.  
 

According to the American Hospital Association, over 34 million patients were admitted to U.S. hospitals for both critical and non-critical procedures in 2022. Consequently, the high rate of hospital admissions is said to drive market growth of cannula throughout the forecast period.
 

The overall healthcare landscape has witnessed a notable surge in surgical procedures necessitating oxygen support in recent years. There has been a significant increase in the number of surgeries wherein patients require supplemental oxygen. This rise is attributed to several factors, including an aging population base with a higher prevalence of respiratory issues, an increase in complex surgical interventions, and the expanding scope of elective procedures.
 

The demand for oxygen support during surgeries underscores the critical importance of ensuring optimal oxygenation for patients undergoing various medical interventions. This trend emphasizes the need for healthcare facilities to adapt and enhance their infrastructure and resources to meet the growing requirements of oxygen-dependent surgical procedures.
 

COVID-19 Impact

The COVID-19 pandemic significantly impacted the nasal cannula market. The surge in respiratory distress cases led to a heightened demand for oxygen delivery devices, with nasal cannulas playing a crucial role. Hospitals faced challenges in managing the influx of patients, leading to strain on resources and disruption in the supply chain. The pandemic prompted a shift toward homecare settings, increasing the need for portable nasal cannulas.
 

Nasal Cannula Market Trends

The increasing home healthcare adoption of nasal cannulas reflects a broader trend towards patient-centred care, emphasizing comfort, accessibility, and cost-effectiveness. As technology and healthcare delivery models continue to evolve, the role of nasal cannulas in home-based respiratory care is anticipated to expand further.
 

• The development of portable and user-friendly nasal cannula devices has facilitated their use in home settings. Compact and battery-operated options provide patients with greater mobility and independence.
   
• Home healthcare, including the use of nasal cannulas, is often more cost-effective than prolonged hospitalization. The shift towards home-based care helps optimize healthcare resources and reduces the burden on hospital facilities.
   
• The COVID-19 pandemic accelerated the adoption of home healthcare solutions, including nasal cannulas. Concerns about infection risks in healthcare settings prompted a preference for home-based care whenever feasible.
   
• Educational efforts by healthcare providers have empowered patients to manage their respiratory conditions at home. Training programs and informational resources on the proper use of nasal cannulas have contributed to increased adoption.
   

Nasal Cannula Market Analysis 

The market by type is categorized into low flow and high flow nasal cannula. The low flow nasal cannula segment garnered USD 5.4 billion revenue size in the year 2022.
 

• Low flow nasal cannulas continue to be widely used, particularly in chronic conditions such as chronic obstructive pulmonary disease (COPD) and sleep apnea. The versatility and comfort of low flow nasal cannulas make them a preferred choice for long-term oxygen therapy.
   
• The high flow nasal cannula segment is experiencing a notable increase in demand. This is attributed to the effectiveness of high flow nasal cannula in providing higher rates of oxygen flow, making it suitable for a range of clinical applications, including acute respiratory failure and critical care settings.
   
• The market, encompassing both low flow and high flow types, is witnessing growth in developing regions.
   

Moreover, rising awareness, improving healthcare infrastructure, and rising healthcare expenditure further contributes to market expansion.
 

Based on material, the nasal cannula market is segmented into plastic and silicone. The plastic segment dominated the market and accounted for over 63% business share in the year 2022.
 

• Plastic nasal cannulas are often more cost-effective to manufacture compared to silicone alternatives. This cost advantage appeals to healthcare providers and manufacturers, particularly in environments wherein budget considerations play a significant role.
   
• Plastic nasal cannulas have been widely used and accepted in clinical settings for several years. Their long-standing presence in the market has contributed to a high level of familiarity among healthcare professionals, leading to continued adoption.
   

Based on application, the nasal cannula market is segmented into acute respiratory failure, chronic obstructive pulmonary disease (COPD), anesthesia, carbon monoxide toxicity, sleep apnea, acute heart failure, and other applications. The COPD segment accounted for over 27% business share in the year 2022.
 

• The increasing prevalence of COPD globally is a significant driver for the market. As COPD becomes more prevalent, the demand for respiratory support devices, including nasal cannulas, rises to manage symptoms and improve patients' quality of life.
   
• There is a noticeable shift towards home-based management of COPD, driven by the desire to reduce hospitalizations and enhance patient comfort. Nasal cannulas, being a non-invasive and effective oxygen delivery method, play a crucial role in supporting COPD patients in homecare settings.
   

Based on end-use, the nasal cannula market is segmented into hospitals, specialty clinics, long-term care centres, ambulatory care centres, homecare settings, and other end-users. The hospitals segment accounted for over 35% revenue share in the year 2022.
 

• The trend towards hospital and ambulatory surgical centers has been growing, due to factors such as the aging population, and advancements in portable medical devices. Nasal cannulas are often used in these settings for patients requiring supplemental oxygen therapy.
   
• Increasing awareness among healthcare professionals and patients about the benefits of early diagnosis and treatment of respiratory conditions could contribute to market growth. Education initiatives about the proper use of nasal cannulas and related devices may also play a significant role.
   

U.S. nasal cannula market accounted for over USD 2.9 billion revenue size in 2022 and is predicted to witness substantial market progress.
 

• Manufacturers are increasingly focusing on designing nasal cannulas that are comfortable for patients to wear for extended periods. Improved materials and designs that reduce skin irritation and pressure points are becoming more prevalent.
   
• Changes in healthcare policies, reimbursement structures, and insurance coverage can influence the adoption and usage of medical devices. Nasal cannulas being a commonly used device may be affected by such policy changes.
   

Moreover, the aging population base in the U.S. has been a significant factor driving the demand for medical devices, including nasal cannulas. As individuals age, there is an increased likelihood of respiratory conditions that may require oxygen therapy.
 

Nasal Cannula Market Share

The nasal cannula industry is fragmented, with key players including Becton, Dickinson and Company and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, the U.S. National Institutes of Health (NIH) and the World Health Organization (WHO) have both recommended the consideration of High-Flow Nasal Cannula (HFNC) therapy, as a viable alternative for delivering respiratory support to specific COVID-19 patients that may not find conventional oxygen therapy to be adequate.
 

Some of the eminent market participants operating in the nasal cannula industry include

• Salter Labs
• Teleflex Incorporated
• Becton, Dickinson and Company
• Westmed, Inc.
• Flexicare Medical Limited
• Besmed Health Business Corp.
• Drive DeVilbiss Healthcare
• Smiths Medical
• Medtronic PLC
• Sorin Group
• Masimo Corporation
   

Nasal Cannula Industry News

• In August 2021, ResMed, a leading medical device company, introduced the AirSense 11 in the United States. This device represents the company's latest generation positive airway pressure (PAP) device, specifically designed to provide advanced therapy for the treatment and management of sleep apnea.
   
• In February 2021, softFlow high-flow nasal cannula therapy was launched in the U.S. by Masimo. The device is designed to provide humidified high flow respiratory gases to patients. Such strategies help the company to gain competitive edge along with sustaining its position in the market.
   

Nasal cannula market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Type, 2018 – 2032 (USD Million)

• Low flow nasal cannula
• High flow nasal cannula

By Material, 2018 – 2032 (USD Million)

• Plastic
• Silicone

By Application, 2018 – 2032 (USD Million)

• Acute respiratory failure
• Chronic obstructive pulmonary disease (COPD)
• Anesthesia
• Carbon monoxide toxicity
• Sleep apnea
• Acute heart failure
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Hospitals
• Specialty clinics
• Long-term care centers
• Ambulatory care centers
• Homecare settings
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa